Black Diamond Therapeutics Announces Changes to Board of Directors
April 11, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of...
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
April 07, 2024 18:00 ET
|
Black Diamond Therapeutics, Inc
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
April 03, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target...
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 12, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired...
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
March 05, 2024 16:30 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of...
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of...
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
January 04, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Designation granted for BDTX-1535 as second-line treatment for...
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
December 13, 2023 07:00 ET
|
Black Diamond Therapeutics, Inc
Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 07, 2023 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target...
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 06, 2023 07:45 ET
|
Black Diamond Therapeutics, Inc
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023...